Main Uses and Therapeutic Intent

Synoart is a viscoelastic supplement designed to manage symptoms associated with joint degeneration. It is primarily used to address discomfort and restricted mobility in synovial joints, most commonly the knee. The treatment is intended for patients who experience persistent joint pain that has not responded sufficiently to conservative non-pharmacological therapies or simple analgesics.

The primary therapeutic goal is to supplement the synovial fluid within the joint capsule. In healthy joints, synovial fluid acts as a lubricant and a shock absorber. In conditions such as osteoarthritis, the quality of this fluid diminishes, leading to increased friction and mechanical stress on the cartilage. Synoart aims to restore the rheological properties of the joint environment.

Benefits and Physiological Impact

Improved Lubrication and Shock Absorption

By introducing high-molecular-weight sodium hyaluronate into the joint space, Synoart helps normalize the viscosity of the synovial fluid. This improved lubrication reduces the mechanical friction between the articular surfaces during movement.

Pain Reduction

Many patients experience a decrease in chronic joint pain following the administration of Synoart. This effect is attributed to the protective coating the substance provides over the sensory receptors of the synovial membrane, as well as the reduction of mechanical irritation within the joint.

Enhancement of Mobility

As a result of decreased pain and improved mechanical function, Synoart can help restore a greater range of motion. This allows individuals to engage more comfortably in daily physical activities and may contribute to a better overall quality of life regarding joint health.

Protection of Articular Tissues

While the treatment is symptomatic, the restoration of a stable viscoelastic environment may help protect the remaining cartilage from the accelerated wear caused by inadequate lubrication. It serves as a temporary physical buffer against the stresses of weight-bearing and repetitive motion.

Regulatory References

1. U.S. Food and Drug Administration (FDA) for a related sodium hyaluronate product

Eligibility Map: Who can and cannot use Synoart — official regulatory information

This section describes the official eligibility and non-eligibility information for Synoart, strictly based on governmental regulatory documents.

---

Populations for Whom Use is Prohibited or Restricted

Contraindicated: You must not use this medicine if you have a known hypersensitivity or allergy to hyaluronate preparations (hyaluronic acid products) or to gram-positive bacterial proteins. The injection is also strictly contraindicated if the knee joint is infected or if there is skin disease or infection at the intended injection site.

Special Consideration/Not Recommended: Use is generally not recommended for patients with active inflammatory arthritis or an acute exacerbation of osteoarthritis. If the joint has significant fluid accumulation (effusion), this condition should be treated and resolved before receiving the injection.

Age and Physiological States: Safety and effectiveness have not been established for the pediatric population. Additionally, use is not established for pregnant women or women who are nursing (lactation). This lack of established data restricts use in these groups.

---

Summary of Eligibility Profile

Official regulatory documents define strict eligibility based primarily on the local condition of the target joint and the potential for allergic reactions. Absolute prohibitions apply when there is an infection risk from the injection procedure or a known allergy to the product’s components. For pediatric, pregnant, and lactating populations, the medicine is restricted because official regulatory safety and efficacy profiles have not been formally established.

Interactions with other medicines and products

Official regulatory information regarding Synoart, an intra-articular viscosupplement, indicates that its interaction profile is predominantly local, which is consistent with its route of administration into the joint space. This local action means that systemic drug interactions are not typically documented in prescribing information.

Local Chemical Incompatibility

The most significant and formally documented interaction is a local chemical incompatibility. Contact with solutions containing Quaternary Ammonium Salts (QAS) is strictly prohibited during the injection procedure. Substances in this category, which include disinfectants such as Benzalkonium Chloride, must be avoided because they may cause the precipitation of the Sodium Hyaluronate product.

Interaction Scope	Regulatory Status
Systemic Drug-Drug Interactions	None documented
Metabolic Interactions (e.g., CYP)	None documented
Food, Alcohol, or Herbal Products	None documented
Local Chemical Interaction	Officially documented restriction: Avoid QAS

Other Co-Administration Considerations

Regulatory labeling generally confirms that the safety and effectiveness of co-administering this product concurrently with other intra-articular injectables—such as local anesthetics or corticosteroids—have not been established. Due to the minimal systemic absorption, the official prescribing information does not list restrictions or necessary adjustments for orally administered medicines.

Viscoelastic Action and Neurosensory Pathway Modulation

The immediate primary mechanism is viscosupplementation, where the high-molecular-weight polymer physically increases the viscoelasticity of the synovial fluid. This action alters the rheology of the fluid, resulting in decreased frictional forces between articular surfaces. Concurrently, the viscous solution forms a barrier layer over the articular nociceptor terminals, mechanically stabilizing the tissue and dampening their sensitivity, thereby reducing the afferent nerve impulse generation in response to mechanical stimulation.

Cellular Modulation and Catabolic Cascade Regulation

Beyond physical action, the molecule binds to receptors such as CD44 on chondrocytes and synoviocytes. This binding modulates intracellular signaling, initiating an anabolic and catabolic regulation cascade. This involves reducing the synthesis of matrix-degrading enzymes (MMPs and ADAMTS) and pro-inflammatory mediators (e.g., IL-1beta), while stimulating anabolic processes associated with the synthesis of joint matrix components. This mechanism influences the balance of Extracellular Matrix (ECM) turnover and promotes a localized anti-inflammatory state.

Synoart is a food supplement typically presented in tablet form and is intended for oral administration. It is a commercially available formulation containing substances such as hyaluronic acid and unmodified collagen type II.

Administration and Dosage

The recommended dosage for adults is generally one 1500 mg tablet per day taken orally. The tablet should be swallowed whole with water.

Patients should adhere to the daily dosage specified by their healthcare provider or as indicated on the product's official labeling. Individuals are advised to consult their healthcare professional prior to starting any new supplement regimen to ensure it is appropriate for their specific health needs and to avoid potential interactions with other medications or supplements.

Patient Group	Recommended Daily Dose
Adults	One 1500 mg tablet

Important Considerations

• Consistency: For consistent absorption, it is advisable to take the supplement at approximately the same time each day.
• Missed Dose: In the event of a missed dose, the next scheduled dose should be taken at the regular time. Do not double the dose to compensate for the one missed.

Research Evidence / Overview of Studies

Research and Study Design

Research studies explored the drug's potential interaction with a specific inflammatory pathway. Early research evaluated the compound's activity in various laboratory models. The activity of the compound was investigated regarding its interaction with the intended target. Clinical trials explored the assessment of pre-defined inflammatory markers and evaluated whether the drug was associated with changes in overall pain scores after a 12-week treatment period compared to a control group.

Combination Therapy Trials

Investigators explored the drug’s potential use alongside an existing standard-of-care medication. Studies investigated whether this combination was associated with changes in measured disease indicators for individuals with advanced disease. The study design included an analysis of primary and secondary endpoints.

---

Safety and Tolerability Profiles

The research results indicated that the drug performed differently than both placebo and certain comparator treatments.

Adverse Events Reporting

Clinical studies noted the occurrence of side effects. The research documented the frequency of reported adverse events, including gastrointestinal effects and changes in laboratory parameters. The trials included measurement of the rate of treatment discontinuation due to adverse events.

Special Populations

Research examined different dosage regimens, including the dose most frequently evaluated in clinical studies, in both adult and geriatric populations. Studies included older adults to investigate the drug's profile within this specific population. The research did not evaluate the drug in individuals with severe liver impairment.

Common questions about Synoart (FAQ)

Q: Is Synoart considered a first-line treatment for its approved condition?

Official regulatory documents state that viscosupplementation products, which contain Sodium Hyaluronate, are described as being indicated for patients whose joint pain from osteoarthritis is not adequately managed by conservative therapies. This includes non-pharmacologic treatment and simple pain relievers, such as acetaminophen.

---

Q: How quickly can a person expect to feel the effects of Synoart?

The physical action of the product begins immediately in the joint to provide lubrication and cushioning. However, the onset of clinical benefit (pain relief) may be delayed, as studies suggest the full therapeutic effect takes time compared to other types of injection treatments.

---

Q: What is the expected duration of the benefit from Synoart after taking it?

The duration of relief can vary significantly among individuals. Studies suggest that the reduction in pain and related improvement in joint function may last for several months, such as six months or longer, following the recommended course of treatment.

---

Q: Can stopping Synoart suddenly cause any unexpected effects?

Since Synoart is a viscosupplement (a mechanical product injected locally into the joint) and not a systemic medicine, sudden discontinuation is not associated with typical systemic withdrawal or rebound effects. The effect of the product in the joint will naturally diminish over time as the substance degrades. No typical systemic withdrawal or rebound effects are reported.

---

Q: Does Synoart have any potential risk of dependency or withdrawal effects?

Official safety and adverse reaction profiles for this class of product do not list any reports of dependency or withdrawal effects. This is consistent with its mechanical mode of action, which results in minimal absorption into the rest of the body.

---

Q: Can someone with a history of high blood pressure or heart problems use Synoart?

Contraindications for this product focus primarily on local joint conditions and known hypersensitivity to the components. Due to the product's minimal systemic absorption, the official prescribing information does not typically list systemic restrictions related to high blood pressure or other heart problems.

---

Q: Where can I find summaries of the clinical trial data for Synoart?

Summaries of the clinical trials, including information on the study design and the outcomes measured, can be found through official government resources. This information is often available on public registries like ClinicalTrials.gov (by searching for the active ingredient) and within the full regulatory approval documents.

---

Q: Is Synoart still being studied for its current approved uses?

Studies are often ongoing for the product’s active ingredient and class of products. This research typically includes post-market studies, registries, and trials that focus on specific groups of patients or on long-term outcomes to further evaluate the product's profile.

---

Q: Does taking Synoart affect my ability to get a routine vaccine?

The official prescribing information does not list restrictions regarding the receipt of routine vaccines. Because the product works locally within the joint, it is not expected to interfere with the systemic immune response required for vaccination.

---

Q: Is long-term use of Synoart associated with any specific organ risk?

Official safety data indicates that the product’s mechanical and local action, coupled with minimal systemic absorption, means it is not typically associated with long-term toxicity to major internal organs. The rare serious adverse events reported are usually related to the joint injection procedure itself.

---

Q: Do lifestyle factors, like exercise, impact the effectiveness of Synoart?

Official product labeling often includes recommendations regarding physical activity following the injection. To minimize inflammation and support the product's function, official labeling advises patients to avoid strenuous or prolonged weight-bearing activities for a period (e.g., 48 hours) following the procedure.

The storage and disposal of Synoart (Sodium Hyaluronate solution) are regulated to maintain the product’s sterility and physical quality.

---

Official Storage and Disposal Instructions

Storage Requirement	Rule as Documented in Regulatory Labels
Temperature & Light	Store in the original packaging (protected from light) at or below 77 F (25 C).
Prohibited Condition	DO NOT FREEZE. The product must be kept away from freezing temperatures.
Stability Rule	The syringe is for single use only. The sterile contents must be used immediately once the packaging is opened.
Integrity Check	Do not use the product if the sterile package is opened or damaged.
Disposal	Discard the syringe and any unused Synoart after use according to national and local requirements for medical waste disposal.

These rules define Synoart as a product with strictly limited stability once its sterile seal is broken. The mandated storage temperature and the prohibition against freezing are crucial for maintaining the solution's quality. Unused portions and the syringe must be properly discarded as per official guidelines.